Some aflibercept biosimilars are already licensed in the UK, for all Eylea indications, except retinopathy of prematurity. However, they cannot be launched and marketed until Eylea 2mg patent exclusivity expires.

Read our article covering licenced indications, supporting evidence and differences between the aflibercept 2mg biosimilars that will be available for use in the NHS. You must be logged in with an NHS email to view this article.

Heading H1 (XL)

Some aflibercept biosimilars are already licensed in the UK, for all Eylea indications, except retinopathy of prematurity. However, they cannot be launched and marketed until Eylea 2mg patent exclusivity expires.

Heading H2 (L)

Some aflibercept biosimilars are already licensed in the UK, for all Eylea indications, except retinopathy of prematurity. However, they cannot be launched and marketed until Eylea 2mg patent exclusivity expires.

Heading H3 (M)

Some aflibercept biosimilars are already licensed in the UK, for all Eylea indications, except retinopathy of prematurity. However, they cannot be launched and marketed until Eylea 2mg patent exclusivity expires.

Heading H4 (S)

Some aflibercept biosimilars are already licensed in the UK, for all Eylea indications, except retinopathy of prematurity. However, they cannot be launched and marketed until Eylea 2mg patent exclusivity expires.

/